文献速递心律失常

AZALEA-TIMI 71 预设分析:Abelacimab 与利伐沙班在老年房颤患者中的出血风险比较

Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

本研究为 AZALEA-TIMI 71 试验的预设年龄亚组分析,纳入 1287 例房颤患者,比较每月皮下注射 abelacimab(90 mg 或 150 mg)与每日口服利伐沙班(20/15 mg)的出血风险。结果显示,无论 <75 岁还是 ≥75 岁,两种剂量 abelacimab 的主要或临床相关非大出血发生率均显著低于利伐沙班。≥75 岁患者接受 abelacimab 的绝对风险降幅更大,提示 FXI 抑制在高龄房颤患者中可能提供更安全的抗凝策略。

要点

  • ≥75 岁房颤患者中,两种剂量 abelacimab 的主要或临床相关非大出血风险均较利伐沙班显著降低。
  • ≥75 岁患者使用 abelacimab 的出血绝对风险降幅较 <75 岁患者更大。
  • 利伐沙班组出血风险随年龄增加而上升,而 abelacimab 组出血风险随年龄保持稳定。

核心结论

  • 无论年龄分层如何,abelacimab 均较利伐沙班一致减少出血事件。
  • ≥75 岁患者使用 abelacimab 的出血绝对风险降幅可能更大。
  • FXI 抑制可能成为高龄、高出血风险房颤患者尤其有吸引力的抗凝选择。
  • 需要正在进行的 3 期试验结果确认 abelacimab 的疗效和获益-风险比。

研究设计与样本

  • 该预设分析基于 2b 期 AZALEA-TIMI 71 随机临床试验,入组时间为 2021 年 3 月至 2023 年 9 月。
  • 共 1287 例房颤患者随机接受每月皮下注射 abelacimab 90 mg、abelacimab 150 mg 或每日口服利伐沙班 20/15 mg。
  • 出血风险按年龄连续变量及分类变量(<75 岁 vs ≥75 岁)进行评估。
  • 数据分析于 2025 年 2 月至 5 月完成,试验注册号为 NCT04755283。

主要发现

  • 1287 例患者中男性 715 例(55.6%),女性 572 例(44.4%),≥75 岁者 625 例(49%)。
  • 与 <75 岁患者相比,≥75 岁患者体重指数更低(28 vs 32),基线抗血小板使用比例更低(17% vs 32%)。
  • ≥75 岁患者肌酐清除率 ≤50 mL/min 的比例高于 <75 岁患者(33% vs 8%)。
  • ≥75 岁组中,abelacimab 90 mg 和 150 mg 较利伐沙班显著减少主要或临床相关非大出血,HR 分别为 0.32(95% CI,0.17-0.60)和 0.40(95% CI,0.22-0.73)。

关键数值与推荐

  • 主要终点为主要或临床相关非大出血复合终点。
  • ≥75 岁患者中,abelacimab 90 mg 和 150 mg 较利伐沙班的出血绝对风险降幅分别为每 100 患者年 7.1 和 6.2 次。
  • <75 岁患者中,abelacimab 90 mg 和 150 mg 较利伐沙班的出血绝对风险降幅分别为每 100 患者年 4.7 和 4.2 次。

临床怎么用

  • 高龄房颤患者出血风险较高,选择抗凝策略时应考虑出血风险与年龄的关系。
  • 对于出血风险较高的老年房颤患者,FXI 抑制可能提供更安全的替代方案。
  • 临床决策仍应等待 3 期试验疗效和安全性数据确认后再调整常规实践。

局限性

  • 该分析为 2b 期试验的预设亚组分析,样本量有限。
  • 需要 3 期试验结果确认 abelacimab 的疗效和获益-风险比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Older age is a strong risk factor for bleeding with currently available anticoagulants. Factor XI (FXI) inhibition may offer a safer anticoagulant strategy in this population. OBJECTIVE: To evaluate the safety of the novel FXI inhibitor abelacimab vs rivaroxaban by age in patients with atrial fibrillation (AF). DESIGN, SETTING, AND PARTICIPANTS: The randomized clinical trial AZALEA-TIMI 71 randomized patients with AF to receive 1 of 2 subcutaneous abelacimab doses (90 mg or 150 mg monthly) or oral rivaroxaban (20 mg daily, dose reduction to 15 mg). This prespecified analysis of the phase 2b AZALEA-TIMI 71 trial evaluated bleeding risk by age, analyzed continuously and categorically (<75 vs ≥75 years). The trial was conducted from March 2021 to September 2023; data analysis was performed from February to May 2025. INTERVENTIONS: Monthly subcutaneous abelacimab (90 or 150 mg) or daily oral rivaroxaban (20/15 mg). MAIN OUTCOMES AND MEASURES: The primary end point was the composite of major or clinically relevant nonmajor (CRNM) bleeding. RESULTS: Among 1287 patients randomized, 715 (55.6%) were male and 572 (44.4%) were female; there were 625 patients (49%) 75 years or older. Compared with younger patients, those 75 years or older had lower body mass index (28 vs 32), were less likely to be taking antiplatelet therapy at baseline (17% vs 32%), and were more likely to have creatinine clearance 50 mL/min or less (33% vs 8%). Both abelacimab doses were associated with significantly less major or CRNM bleeding compared with rivaroxaban in those 75 years or older (hazard ratio [HR], 0.32; 95% CI, 0.17-0.60; and HR, 0.40; 95% CI, 0.22-0.73; for abelacimab, 90 and 150 mg, vs rivaroxaban, respectively) and in those younger than 75 years (HR, 0.28; 95% CI, 0.12-0.61; and HR, 0.35; 95% CI, 0.17-0.70; P for interaction, .85 and .84, respectively). Patients 75 years or older tended to derive greater absolute risk reductions with abelacimab (7.1 and 6.2 per 100 patient-years for abelacimab, 90 and 150 mg, vs rivaroxaban, respectively) than those younger than 75 years (4.7 and 4.2 per 100 patient-years, respectively). When modeled continuously, bleeding risk tended to increase with age in the rivaroxaban group but remained stable in the abelacimab group (P for interaction, .33). CONCLUSIONS AND RELEVANCE: This study found that abelacimab consistently reduced bleeding compared with rivaroxaban regardless of age, with the potential for a greater absolute reduction in bleeding with older age. FXI inhibition with abelacimab may become a particularly attractive option in older patients with AF and higher bleeding risk. The results of ongoing phase 3 trials are necessary to establish the efficacy and benefit-to-risk ratio of abelacimab. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04755283.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Al Said, Patel, Giugliano, et al. Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. JAMA Cardiol. 2026. PMID: 41637102. doi:10.1001/jamacardio.2025.5418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。